Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.